Literature DB >> 28358736

HIV type 2 epidemic in Spain: challenges and missing opportunities.

Carmen de Mendoza1, Teresa Cabezas, Estrella Caballero, Silvia Requena, María J Amengual, María Peñaranda, Ana Sáez, Raquel Tellez, Ana B Lozano, Ana Treviño, José M Ramos, José L Pérez, Pablo Barreiro, Vicente Soriano.   

Abstract

: HIV type 2 (HIV-2) is a neglected virus despite estimates of 1-2 million people infected worldwide. HIV-2 is less efficiently transmitted than HIV-1 by sex and from mother to child. Although AIDS may develop in HIV-2 carriers, it takes longer than in HIV-1-infected patients. In contrast with HIV-1 infection, there is no global pandemic caused by HIV-2, as the virus is largely confined to West Africa. In a less extent and due to socioeconomic ties and wars, HIV-2 is prevalent in Portugal and its former colonies in Brazil, India, Mozambique and Angola. Globally, HIV-2 infections are steadily declining over time. A total of 338 cases of HIV-2 infection had been reported at the Spanish HIV-2 registry until December 2016, of whom 63% were men. Overall 72% were sub-Saharan Africans, whereas 16% were native Spaniards. Dual HIV-1 and HIV-2 coinfection was found in 9% of patients. Heterosexual contact was the most likely route of HIV-2 acquisition in more than 90% of cases. Roughly one-third presented with CD4 cell counts less than 200 cells/μl and/or AIDS clinical events. Plasma HIV-2 RNA was undetectable at baseline in 40% of patients. To date, one-third of HIV-2 carriers have received antiretroviral therapy, using integrase inhibitors 32 individuals. New diagnoses of HIV-2 in Spain have remained stable since 2010 with an average of 15 cases yearly. Illegal immigration from Northwestern African borders accounts for over 75% of new HIV-2 diagnoses. Given the relatively large community of West Africans already living in Spain and the continuous flux of immigration from endemic regions, HIV-2 infection either alone or as coinfection with HIV-1 should be excluded once in all HIV-seroreactive persons, especially when showing atypical HIV serological profiles, immunovirological disconnect (CD4 cell count loss despite undetectable HIV-1 viremia) and/or high epidemiological risks (birth in or sex partners from endemic regions).

Entities:  

Mesh:

Year:  2017        PMID: 28358736     DOI: 10.1097/QAD.0000000000001485

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  5 in total

1.  Comparison of the Antiviral Activity of Bictegravir against HIV-1 and HIV-2 Isolates and Integrase Inhibitor-Resistant HIV-2 Mutants.

Authors:  Robert A Smith; Dana N Raugi; Vincent H Wu; Christopher G Zavala; Jennifer Song; Khardiata Mbaye Diallo; Moussa Seydi; Geoffrey S Gottlieb
Journal:  Antimicrob Agents Chemother       Date:  2019-04-25       Impact factor: 5.191

2.  Novel assays to investigate the mechanisms of latent infection with HIV-2.

Authors:  Michael D Lu; Sushama Telwatte; Nitasha Kumar; Fernanda Ferreira; Holly Anne Martin; Gayatri Nikhila Kadiyala; Adam Wedrychowski; Sara Moron-Lopez; Tsui-Hua Chen; Erin A Goecker; Robert W Coombs; Chuanyi M Lu; Joseph K Wong; Athe Tsibris; Steven A Yukl
Journal:  PLoS One       Date:  2022-04-27       Impact factor: 3.752

3.  HIV-2 Primary Infection in a French 69-Year-Old Bisexual Man.

Authors:  Nicolas Cazals; Quentin Le Hingrat; Bruno Abraham; Patricia Da Silva; Laure Guindre; Sylvie Goffart; Florence Damond; Benoît Visseaux; Charlotte Charpentier; Sylvie Ranger-Rogez; Diane Descamps
Journal:  Open Forum Infect Dis       Date:  2018-09-11       Impact factor: 3.835

Review 4.  AIDS Clinical Research in Spain-Large HIV Population, Geniality of Doctors, and Missing Opportunities.

Authors:  Vicente Soriano; José M Ramos; Pablo Barreiro; Jose V Fernandez-Montero
Journal:  Viruses       Date:  2018-05-30       Impact factor: 5.048

5.  Assessment of NKG2C copy number variation in HIV-1 infection susceptibility, and considerations about the potential role of lacking receptors and virus infection.

Authors:  Bruno Toson; Rafael T Michita; Maria C T Matte; Robson Soares; Gabriela K S Lawisch; Vanessa S Mattevi; José A B Chies
Journal:  J Hum Genet       Date:  2022-03-22       Impact factor: 3.755

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.